Future directions might include the evaluation of thresholds in other evolving clinical scenarios such as prodromal patients, those with rapid eye movement sleep behavior disorder (RBD), or patients who have tested positive on new synuclein tests [36]. The gene discussed is SNCA; the disease is REM sleep behavior disorder.